A Mycobacterium tuberculosis (H37Rv)-infected guinea pig model was used to screen for targeted delivery to the lungs by insufflation (with lactose excipient) or nebulization, of either rifampicin alone, rifampicin within poly(lactide-co-glycolide) microspheres (R-PLGA) or polymer microparticles alone (PLGA). Animals treated with single and double doses of R-PLGA microspheres exhibited significantly reduced numbers of viable bacteria, inflammation and lung damage compared with lactose-, PLGA- or rifampicin-treated animals 28 days post-infection (P < 0.05). Two doses of R-PLGA resulted in reduced splenic enlargement. These studies support the potential of R-PLGA delivered to the lung to treat pulmonary tuberculosis
Airways delivery of rifampicin microparticles for the treatment of tuberculosis
Suarez, S., O'Hara, P., Kazantseva, M., Newcomer, CE., Hopfer, R., McMurray, DN., & Hickey, A. (2001). Airways delivery of rifampicin microparticles for the treatment of tuberculosis. Journal of Antimicrobial Chemotherapy, 48(3), 431-434. https://doi.org/10.1093/jac/48.3.431
Abstract
Publications Info
To contact an RTI author, request a report, or for additional information about publications by our experts, send us your request.